N/A
N=24
Effect of Lactose on Blood Lipids
Cardiovascular Risk Factor · Lipaemia · Metabolic Disease
Bottom Line
View on ClinicalTrials.gov: NCT04924530 ↗Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Sep 2024
Primary outcome: Primary: Postprandial Changes in Plasma Triglyceride Concentrations — 51; 90; 98 mmol/L x 360 min
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Maltodextrin (Dietary_supplement); Sucrose (Dietary_supplement); Lactose (Dietary_supplement)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Bath
- Primary completion
- Jul 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Postprandial Changes in Plasma Triglyceride Concentrations |
51; 90; 98 | — |
| SECONDARY Postprandial de Novo Lipogenesis (DNL) |
— | — |
| SECONDARY Dietary Fat Oxidation |
— | — |
| SECONDARY Postprandial Changes in Plasma Insulin Concentrations |
— | — |
| SECONDARY Postprandial Changes in Plasma Glucose Concentrations |
— | — |
| SECONDARY Postprandial Changes in Plasma Galactose Concentrations |
— | — |
| SECONDARY Postprandial Changes in Plasma Fructose Concentrations |
— | — |
| SECONDARY Postprandial Changes in Plasma VLDL-rich Triglyceride [Svedberg Flotation Rate (Sf): 20-400] Concentrations |
— | — |
| SECONDARY Postprandial Changes in Plasma Chylomicron-rich Triglyceride (Sf: >400) Concentrations |
— | — |
| SECONDARY Postprandial Changes in Plasma Lactate Concentrations |
— | — |
| SECONDARY Postprandial Changes in Plasma Non-esterified Fatty Acid Concentrations |
— | — |
| SECONDARY Postprandial Changes in Plasma Beta-hydroxybutyrate Concentrations |
— | — |
| SECONDARY Postprandial Changes in Plasma Uric Acid Concentrations |
— | — |
Summary
This study aims to determine to what extent ingestion of free sugars influence postprandial triglyceridaemia in men and women.
Eligibility Criteria
Inclusion Criteria
- Age: 18-50 years and premenopausal (for women)
Exclusion criteria
- Weight instability (>5 kg change in body mass within last 6 months)
- Diagnosis of any form of diabetes
- Intolerances or allergies to any of the study procedures (e.g. lactose intolerance)
- Galactose disorders (e.g. galactokinase deficiency, UDPgalactose-4-epimerase deficiency, galactose-1-phosphate uridyl transferase deficiency)
- Fructose malabsorption
- Inborn errors of fructose metabolism (e.g. fructokinase deficiency, aldolase B deficiency, fructose-1,6-bisphosphatase deficiency)
- Pregnant or lactating
- Any condition that could introduce bias to the study (e.g. diagnoses of lipid disorders, including cardiovascular disease, or therapies that alter lipid or glucose metabolism, such as statins or niacin).
Data sourced from ClinicalTrials.gov (NCT04924530). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.